Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis
<p>Abstract</p> <p>Background</p> <p>Human menopausal gonadotrophins and recombinant human follicle stimulating hormone are the two main gonadotrophin products utilized for controlled ovarian stimulation in assisted reproductive technologies. In this meta-analysis, the...
Main Authors: | Ezcurra Diego, Schertz Joan C, Lehert Philippe |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-09-01
|
Series: | Reproductive Biology and Endocrinology |
Online Access: | http://www.rbej.com/content/8/1/112 |
Similar Items
-
Comparison of Human Menopausal Gonadotrophin and Recombinant Follicle-Stimulating Hormone in In-Vitro Fertilisation and Pregnancy Outcome
by: Phakphum Phophong, et al.
Published: (2020-08-01) -
Comparison of Effectiveness between Recombinant Follicle Stimulating Hormone and Human Menopausal Gonadotrophin Administration in those with Diminished Ovarian Reserve
by: Phakphum Ponphong, et al.
Published: (2002-01-01) -
In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review
by: Blackmore Stuart, et al.
Published: (2010-11-01) -
Economic evaluation of highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone in fresh and frozen in vitro fertilization/intracytoplasmic sperm-injection cycles in Sweden
by: Wex J, et al.
Published: (2013-08-01) -
The Human Oocyte Preservation Experience (HOPE) a phase IV, prospective, multicenter, observational oocyte cryopreservation registry
by: Ezcurra Diego, et al.
Published: (2009-05-01)